The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose

Immunization with mRNA SARS-CoV-2 vaccines has been highly recommended and prioritized in fragile subjects, including patients with myelofibrosis (MF). Available data on the vaccine immune response developed by MF patients and the impact of ruxolitinib treatment are still too fragmented to support a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorino, Fabio, Sicuranza, Anna, Ciabattini, Annalisa, Santoni, Adele, Pastore, Gabiria, Simoncelli, Martina, Polvere, Jacopo, Galimberti, Sara, Auddino, Stefano, Baratè, Claudia, Montagnani, Francesca, Sammartano, Vincenzo, Bocchia, Monica, Medaglini, Donata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533286/
https://www.ncbi.nlm.nih.gov/pubmed/34680595
http://dx.doi.org/10.3390/biomedicines9101480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533286/
https://www.ncbi.nlm.nih.gov/pubmed/34680595
http://dx.doi.org/10.3390/biomedicines9101480

Ejemplares similares